Lurbinectedin Disease Interactions
There are 2 disease interactions with lurbinectedin.
Lurbinectedin (applies to lurbinectedin) liver dysfunction
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
The use of lurbinectedin can cause hepatotoxicity. Assess liver function tests, before administering lurbinectedin, periodically during treatment, and as clinically indicated. No dose adjustment is recommended for patients with mild hepatic impairment. Caution is recommended when using this agent in patients with moderate or severe hepatic impairment as the pharmacokinetics of lurbinectedin have not been studied in these patients. Withhold, reduce the dose, or permanently discontinue lurbinectedin based on severity.
Lurbinectedin (applies to lurbinectedin) myelosuppression
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts
The use of lurbinectedin can cause myelosuppression. Assess blood counts, including neutrophil count and platelet count before each therapy and administer lurbinectedin only to patients with baseline neutrophil count of at least 1,500 cells/mm3 and platelet count of at least 100,000/mm3. For neutrophil count less than 500 cells/mm3 or any value less than lower limit of normal, the use of G-CSF is recommended. Withhold, reduce the dose, or permanently discontinue lurbinectedin based on severity.
Switch to professional interaction data
Lurbinectedin drug interactions
There are 442 drug interactions with lurbinectedin.
Lurbinectedin alcohol/food interactions
There is 1 alcohol/food interaction with lurbinectedin.
More about lurbinectedin
- lurbinectedin consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: alkylating agents
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Imfinzi
Imfinzi (durvalumab) is an immunotherapy used to treat types of lung cancer (NSCLC, SCLC), bile ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Tecentriq
Tecentriq (atezolizumab) is a monoclonal antibody used to treat non-small cell lung cancer, small ...
Otrexup
Otrexup is used for polyarticular juvenile idiopathic arthritis, psoriasis, rheumatoid arthritis
Trexall
Trexall is used for acute lymphoblastic leukemia, acute lymphocytic leukemia, breast cancer ...
Etoposide
Etoposide systemic is used for cancer, hodgkin's lymphoma, multiple myeloma, ovarian cancer, small ...
Durvalumab
Durvalumab (Imfinzi) is an immunotherapy used to treat lung cancer (NSCLC, SCLC) and other cancers ...
Atezolizumab
Atezolizumab (Tecentriq) is a type of immunotherapy drug that helps the body's immune system to ...
Cyclophosphamide
Cyclophosphamide systemic is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.